Caris Life Sciences, Inc.(CAI)
$18.54-0.96 (-4.92%)
CAI
Caris Life Sciences, Inc. financials statements
$18.54
At close:-0.96 (-4.92%)
Want to see CAI full AI Analyst Report?
Caris Life Sciences, Inc. (CAI) Ratios
193 Followers
Caris Life Sciences, Inc. Ratios
CAI's free cash flow for Q3 2026 was $-39.72M. For the 2026 fiscal year, CAI's free cash flow was decreased by $-17.47M and operating cash flow was $-22.25M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.85 | 1.30 | 2.55 | 3.77 | 0.67 |
| Quick Ratio | 7.85 | 1.06 | 2.04 | 3.43 | 0.67 |
| Cash Ratio | 6.27 | 0.39 | 0.59 | 0.78 | 0.17 |
| Solvency Ratio | -0.94 | -0.08 | -0.11 | -0.11 | 0.07 |
| Operating Cash Flow Ratio | 0.65 | -1.48 | -2.90 | -2.09 | 0.86 |
| Short-Term Operating Cash Flow Coverage | 492.04 | -4.09 | -1653.29 | -5.41 | 1.51 |
| Net Current Asset Value | $ 449.44M | $ -2.63B | $ -2.32B | $ -1.90B | $ -1.70B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.34 | 1.23 | 0.53 | 0.38 | 0.67 |
| Debt-to-Equity Ratio | 0.66 | -0.17 | -0.10 | -0.16 | 2.49 |
| Debt-to-Capital Ratio | 0.40 | -0.20 | -0.11 | -0.19 | 0.71 |
| Long-Term Debt-to-Capital Ratio | 0.40 | -0.15 | -0.08 | -0.11 | 0.69 |
| Financial Leverage Ratio | 1.95 | -0.14 | -0.19 | -0.42 | 3.72 |
| Debt Service Coverage Ratio | -8.04 | -1.66 | -8.21 | -3.09 | 1.03 |
| Interest Coverage Ratio | 0.79 | -5.14 | -10.11 | -11.83 | 2.26 |
| Debt to Market Cap | 0.05 | 0.05 | 0.02 | 0.03 | 3.47 |
| Interest Debt Per Share | 1.54 | 1.86 | 0.98 | 1.17 | 100.69 |
| Net Debt to EBITDA | -36.80 | -1.97 | -0.62 | -0.67 | 6.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 66.40% | 43.37% | 29.17% | 30.96% | 62.64% |
| EBIT Margin | -1.38% | -56.24% | -101.20% | -113.80% | 48.91% |
| EBITDA Margin | 1.40% | -44.38% | -85.19% | -95.13% | 86.55% |
| Operating Profit Margin | 5.56% | -62.37% | -104.38% | -122.16% | 47.31% |
| Pretax Profit Margin | -8.38% | -68.38% | -111.53% | -124.12% | 10.04% |
| Net Profit Margin | -66.25% | -68.38% | -111.53% | -124.12% | 9.43% |
| Continuous Operations Profit Margin | -66.25% | -68.38% | -111.53% | -124.12% | 9.43% |
| Net Income Per EBT | 790.09% | 100.00% | 100.00% | 100.00% | 93.91% |
| EBT Per EBIT | -150.93% | 109.63% | 106.84% | 101.61% | 21.23% |
| Return on Assets (ROA) | -47.79% | -82.01% | -82.69% | -44.72% | 1.06% |
| Return on Equity (ROE) | -93.18% | 11.28% | 15.92% | 18.85% | 3.95% |
| Return on Capital Employed (ROCE) | 4.52% | -144.20% | -100.56% | -54.39% | 6.07% |
| Return on Invested Capital (ROIC) | 4.52% | -105.17% | -98.47% | -49.52% | 5.28% |
| Return on Tangible Assets | -48.63% | -86.90% | -86.75% | -45.96% | 1.06% |
| Earnings Yield | -7.06% | -3.95% | -4.79% | -4.50% | 5.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.24 | 4.67 | 5.54 | 6.43 | 2.04 |
| Payables Turnover | 6.96 | 8.40 | 8.13 | 6.54 | 29.97 |
| Inventory Turnover | 0.00 | 5.90 | 4.43 | 3.80 | 0.00 |
| Fixed Asset Turnover | 12.85 | 4.01 | 2.08 | 1.87 | 0.17 |
| Asset Turnover | 0.72 | 1.20 | 0.74 | 0.36 | 0.11 |
| Working Capital Turnover Ratio | 1.76 | 4.17 | 1.16 | 0.00 | 5.54 |
| Cash Conversion Cycle | -2.04 | 96.55 | 103.50 | 97.07 | 166.96 |
| Days of Sales Outstanding | 50.41 | 78.13 | 65.93 | 56.80 | 179.14 |
| Days of Inventory Outstanding | 0.00 | 61.86 | 82.49 | 96.04 | 0.00 |
| Days of Payables Outstanding | 52.44 | 43.45 | 44.91 | 55.77 | 12.18 |
| Operating Cycle | 50.41 | 139.99 | 148.42 | 152.84 | 179.14 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.29 | -0.96 | -1.08 | -1.12 | 15.43 |
| Free Cash Flow Per Share | 0.24 | -1.00 | -1.17 | -1.29 | 3.21 |
| Dividend Paid and CapEx Coverage Ratio | 5.11 | -29.04 | -12.37 | -6.76 | 1.17 |
| Capital Expenditure Coverage Ratio | 5.11 | -29.04 | -12.37 | -6.76 | 1.26 |
| Operating Cash Flow Coverage Ratio | 0.22 | -0.58 | -1.27 | -1.05 | 0.16 |
| Operating Cash Flow to Sales Ratio | 0.10 | -0.59 | -0.90 | -1.11 | 0.94 |
| Free Cash Flow Yield | 0.88% | -3.56% | -4.19% | -4.60% | 11.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.20 | -25.30 | -20.89 | -22.24 | 18.12 |
| Price-to-Sales (P/S) Ratio | 9.39 | 17.30 | 23.29 | 27.60 | 1.71 |
| Price-to-Book (P/B) Ratio | 13.20 | -2.85 | -3.32 | -4.19 | 0.72 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 113.95 | -28.11 | -23.89 | -21.75 | 8.73 |
| Price-to-Operating Cash Flow Ratio | 91.67 | -29.08 | -25.83 | -24.97 | 1.81 |
| Price-to-Earnings Growth (PEG) Ratio | -0.35 | -0.52 | -1.31 | 0.00 | -1.83 |
| Enterprise Value Multiple | 633.02 | -40.94 | -27.96 | -29.68 | 8.63 |
| Enterprise Value | 7.20B | 7.49B | 7.29B | 7.30B | 2.19B |
| EV to EBITDA | 633.02 | -40.94 | -27.96 | -29.68 | 8.63 |
| EV to Sales | 8.87 | 18.17 | 23.82 | 28.23 | 7.46 |
| EV to Free Cash Flow | 107.69 | -29.53 | -24.43 | -22.25 | 38.13 |
| EV to Operating Cash Flow | 86.63 | -30.55 | -26.41 | -25.54 | 7.92 |
| Tangible Book Value Per Share | 1.97 | -9.89 | -8.50 | -6.76 | 39.12 |
| Shareholders’ Equity Per Share | 2.04 | -9.81 | -8.42 | -6.68 | 39.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -6.90 | 0.00 | 0.00 | 0.00 | 0.06 |
| Revenue Per Share | 2.87 | 1.62 | 1.20 | 1.01 | 16.38 |
| Net Income Per Share | -1.90 | -1.11 | -1.34 | -1.26 | 1.55 |
| Tax Burden | 7.90 | 1.00 | 1.00 | 1.00 | 0.94 |
| Interest Burden | 6.06 | 1.22 | 1.10 | 1.09 | 0.21 |
| Research & Development to Revenue | 0.06 | 0.28 | 0.38 | 0.39 | 0.00 |
| SG&A to Revenue | 0.48 | 0.78 | 0.50 | 0.60 | 0.09 |
| Stock-Based Compensation to Revenue | 0.09 | 0.05 | 0.05 | 0.09 | 0.01 |
| Income Quality | -1.22 | 0.87 | 0.81 | 0.89 | 9.99 |
Currency in USD

